Mediolanum International Funds Ltd Increases Stock Position in Abbott Laboratories $ABT

Mediolanum International Funds Ltd raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 78.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 383,485 shares of the healthcare product maker’s stock after acquiring an additional 169,026 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Abbott Laboratories were worth $51,046,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ABT. Norges Bank purchased a new stake in shares of Abbott Laboratories during the 2nd quarter valued at $3,026,180,000. Laurel Wealth Advisors LLC raised its stake in Abbott Laboratories by 13,347.0% in the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after buying an additional 6,011,891 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after acquiring an additional 2,977,715 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Abbott Laboratories by 180.7% during the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock worth $416,659,000 after acquiring an additional 1,972,097 shares during the last quarter. Finally, TD Asset Management Inc increased its holdings in shares of Abbott Laboratories by 98.6% during the second quarter. TD Asset Management Inc now owns 3,467,896 shares of the healthcare product maker’s stock valued at $471,669,000 after acquiring an additional 1,721,523 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Piper Sandler decreased their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Mizuho boosted their price target on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Royal Bank Of Canada decreased their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Barclays increased their price target on shares of Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $138.40.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $109.31 on Friday. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23. The business’s 50 day moving average is $122.77 and its two-hundred day moving average is $127.46. The company has a market capitalization of $190.08 billion, a P/E ratio of 29.39, a P/E/G ratio of 1.69 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter last year, the business earned $1.34 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a $0.63 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 67.74%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a portfolio reset tied to a deal with Exact Sciences that refocuses its cancer diagnostics strategy — investors appear to view the move as a strategic repositioning that could improve longer‑term growth in diagnostics. Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal
• Positive Sentiment: Freedom Capital upgraded ABT from “hold” to “strong‑buy,” a bullish vote that can attract buy‑side interest and support near‑term buying pressure. Freedom Capital upgrade (Zacks)
• Neutral Sentiment: Analyst commentary and feature pieces are framing Abbott as a steady, dividend‑oriented healthcare name, which reinforces income investor interest but is unlikely to drive a large repricing on its own. Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist
• Neutral Sentiment: Coverage pieces and analyst‑call writeups summarize Q4 takeaways and evolving price targets; useful for longer‑term positioning but largely reiterative. How New Price Targets Are Shaping The Evolving Story For Abbott Laboratories (ABT) 5 Insightful Analyst Questions From Abbott’s Q4 Call
• Neutral Sentiment: Updates projecting “decent organic sales growth” for 2026 support baseline expectations for revenue improvement but are not a catalyst by themselves. Decent organic sales growth expected for Abbott Laboratories (ABT) in 2026
• Negative Sentiment: Daiwa Capital Markets lowered its price target to $113 (from $136) while keeping an “outperform” call — a downward PT revision that can cool momentum and signals reduced near‑term upside expectations. Daiwa Securities adjusts Abbott PT to $113
• Negative Sentiment: Leerink Partners cut its target to $119 (from $136) and moved to “market perform,” another analyst downgrade that adds pressure and contributes to today’s mixed tone. Leerink Partners adjusts Abbott PT to $119 TickerReport coverage

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.